

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 3, 2020

Laura Shawver Chief Executive Officer Silverback Therapeutics, Inc. 500 Fairview Ave N, Suite 600 Seattle, WA 98109

Re: Silverback Therapeutics, Inc.

Registration Statement on Form S-1 Exhibit Nos. 10.10, 10.11, 10.12 Filed November 10, 2020 File No. 333-250009

Dear Dr. Shawver:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance